Trial Profile
Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms EPZSwitch
- 27 Apr 2017 Status changed from recruiting to completed.
- 08 Jun 2012 New trial record